GLUEMonte Rosa Therapeutics, Inc.
Biological Products, (no Diagnostic Substances)
- Revenue
- $124M
- 64% YoY
- Operating margin
- -43.8%
- 59% YoY
- EBITDA
- −$46M
- 37% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired15% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $76M | $124M | 64% |
| Operating income | −$73M | −$112M | −$143M | −$81M | −$54M | 33% |
| Net income | −$74M | −$109M | −$135M | −$73M | −$39M | 47% |
| Operating cash flow | −$59M | −$92M | −$44M | $42M | −$23M | 154% |
| Capex | $10M | $13M | $19M | $4M | $5M | 18% |
| Stock-based comp | $5M | $12M | $17M | $18M | $19M | 4.1% |
| Dividends | $0 | $0 | $0 | $0 | $0 |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $137 · 1
- Net
- −$137
Pay vs performance
No pay-versus-performance disclosure yet.